Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
BioXcel Therapeutics, Inc. (NASDAQ: BTAI)
BTAI Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
327.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%
BTAI Stock Analysis
BTAI
PE Ratio:
BTAI
PEG Ratio:
Not Available
BTAI
Forward EPS Growth (12 month):
0.00%
BTAI
PS Ratio:
52.9
BTAI
PSG Ratio:
0.1
BTAI
Forward Revenue Growth (12 month):
400.00%
BTAI Articles
No data was found